DARUNAVIR GLENMARK 800mg tablets medication leaflet

J05AE10 darunavir • Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors

Darunavir is a protease inhibitor used for the treatment of human immunodeficiency virus (HIV) infection. It works by inhibiting the HIV protease enzyme, which is essential for viral replication, thereby reducing the viral load.

The medication is taken orally, usually once daily, in combination with other antiretroviral drugs. Common side effects include nausea, diarrhea, headaches, and skin rashes.

Darunavir is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with severe hepatic conditions.

This medication is an important option for managing HIV infection, helping to improve patients' quality of life and prevent disease progression.

General data about DARUNAVIR GLENMARK 800mg

Substance: darunavir

Date of last drug list: 01-10-2020

Commercial code: W66885001

Concentration: 800mg

Pharmaceutical form: tablets

Quantity: 30

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PHARAMATHEN S.A. - GRECIA

Holder: GLENMARK PHARMACEUTICALS S.R.O. - REPUBLICA CEHA

Number: 12713/2019/01

Shelf life: 30 months

Pharmaceutical forms available for darunavir

Concentrations available for darunavir

100mg/ml, 150mg, 300mg, 400mg, 600mg, 75mg, 800mg